Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO for skin cancer prevention
NCT00005884Phase 3Completed
- Sponsor
- University of Wisconsin–Madison
- Primary completion
- Dec 2000
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of eflornithine in basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sponsored by University of Wisconsin–Madison. Status: completed.
02
Drugs
eflornithine
03
Conditions
basal cell carcinoma (BCC)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT00005884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005884.